As champagne dries at the Broad Institute and tears are wiped at the University of California, another CRISPR question remains unanswered: What becomes of the companies that picked sides?
Editas Medicine, which has aligned with the winning Broad, saw its share price rise more than 25 percent on Wednesday. Intellia Therapeutics, affiliated with UC, fell about 11 percent, while compatriot CRISPR Therapeutics dipped 24 percent.
If that seems like a fairly mild reaction to what has been billed as biotech’s trial of the century, that’s because investors don’t think the ruling will derail the losers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
